Genentech, a member of the Roche Group (OTC: RHHBY) announced that new data from Actemra (tocilizumab) and Rituxan (rituximab) will ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Corporate News FDA

Needham & Company Raises Price Target on Rogers (ROG) to $75 Following Solid 3Q November 4, 2016 8:26 AM Genentech (RHHBY) to Make 60+ Presentations at ASH 2016; Will Include Phase III GALLIUM Study DataNovember 3, 2016 12:39 PM Rogers (ROG) Tops Q3 EPS by 20cNovember 2, 2016 5:45 PM Genentech to Present New Data on Medicines for Autoimmune Diseases and Severe Inflammatory Disorders at the 2016 ACR/ARHP Annual MeetingNovember 2, 2016 1:00 AM